Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

MiCCrobioTAckle Advancing Research at the Intersection Between Gut Microbiota and Cancer Cachexia to Train Europe’s Future Leaders in Microbiota Medicine

Coordinator
Leibniz-Institut Fur Naturstoff-Forschung Und Infektionsbiologie eV Hans-Knoll-Institut, Germany
Runs
1 November 2024 to 31 October 2028
Status
Running
EU funding
€3.2m
Total cost
—
Partners
28 organisations in 12 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101169068

What the project is doing

In the project's own words, from its summary on CORDIS.

Microbiota medicine is the new frontier in human health. The human gastrointestinal tract is home to trillions of microbes. Under normal conditions, these microbial communities drive physiological and homeostatic functions in the host; when altered, they can lead to severe disorders. With an increasingly recognized role in health and disease, the gut microbiota offers promising therapeutic and diagnostic potential to tackle various pathologies (incl. metabolic, neurological, and cardiovascular disorders).

Its full clinical potential remains largely unrealized though, mostly due to the lack of critical mass capable of integrating the multiple scientific and translational dimensions of microbiota medicine. Grounded on a team of 180leading researchers and entrepreneurs from across 12 countries and dispersed disciplines (biological big data analytics, systems and synthetic biology, experimental and translational medicine), MiCCrobioTAckle will train 12 Doctoral Candidates (DCs) with the much-needed cross-disciplinary and -sectoral expertise to advance microbiota medicine.

As course-setting disease, the DCs will focus on cancer cachexia (CC). CC is an excellent model to study the host-microbiota axis in the context of metabolic diseases and represents the paradigm of a devastating condition in urgent need of new and more efficient means of clinical management. Along MiCCrobioTAckle, the 12 high-calibre DCs will foster new discoveries with impact on CC, while driving scientific and technological progress in microbiota medicine in its broadest scope.

By training the next generation of researchers with out-of-the-box thinking and an entrepreneurial mindset in microbiota medicine, MiCCrobioTAckle will safeguard the EU leadership in this vanguard and imperative biotech/pharma segment, while paving the way for the development of novel gut microbiota insights and tools to tackle multiple diseases with foreseeable impact on the well-being of billions of citizens worldwide.

Topics

Who is involved

OrganisationCityCountryRole
Leibniz-Institut Fur Naturstoff-Forschung Und Infektionsbiologie eV Hans-Knoll-InstitutJenaGermanyCoordinator
Biofaction KgWienAustriaAssociatedpartner
Universite Catholique De LouvainLouvain La NeuveBelgiumAssociatedpartner
Biomarker Technologies (bmk) GmbHMunsterGermanyAssociatedpartner
Deutsches Krebsforschungszentrum HeidelbergHeidelbergGermanyParticipant
Friedrich-Schiller-Universität JenaJenaGermanyAssociatedpartner
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyAssociatedpartner
Abzu ApsNordhavnDenmarkAssociatedpartner
Chr. Hansen ASHorsholmDenmarkAssociatedpartner
Danmarks Tekniske UniversitetKongens LyngbyDenmarkParticipant
DNASense ApSAalborg ØstDenmarkAssociatedpartner
Ms-Omics ApsVedaekDenmarkAssociatedpartner
Snipr Biome ApsCopenhagen ODenmarkAssociatedpartner
Universitat Rovira I VirgiliTarragonaSpainAssociatedpartner
Hun-Ren Szegedi Biologiai KutatokozpontSzegedHungaryParticipant
HUN-REN Szegedi Biologiai KutatokozpontSzegedHungaryParticipant
Reformatus Pulmonologiai CentrumTorokbalintHungaryAssociatedpartner
Semmelweis EgyetemBudapestHungaryAssociatedpartner
Single-Cell Technologies KftSzegedHungaryAssociatedpartner
SeqBiome Ltd.BandonIrelandAssociatedpartner
University College Cork - National University of Ireland, CorkCorkIrelandParticipant
University College Dublin, National University of Ireland, DublinDublinIrelandAssociatedpartner
Fondazione Casa Sollievo Della SofferenzaSan Giovanni Rotondo FgItalyAssociatedpartner
Caelus Pharmaceuticals B.v.ZegveldNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Oslo Cancer Cluster SAOsloNorwayAssociatedpartner
Presymptom Health LtdLeedsUnited KingdomAssociatedpartner
Community InitiativesOaklandUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI